Results 101 to 110 of about 17,264 (156)

QSAR-Guided In Silico Design of Piperazinylanthranilamide Factor Xa Inhibitors: Applicability-Domain Assessment, ADMET Profiling, Molecular Docking, Molecular Dynamics, and MM/GBSA. [PDF]

Int J Mol Sci
Gordon P, Janiak M, Gackowski M, Zielińska-Pisklak M, Szeleszczuk Ł.   +4 more
europepmc   +1 more source

Real-World Assessment of Direct Oral Factor Xa Inhibitors: Dosing Appropriateness, Drug Exposure, and Inter-Platform Comparability of Chromogenic Anti-Xa Assays. [PDF]

Diagnostics (Basel)
Kim Y, Lee S, Park Y, Lee KA.
europepmc   +1 more source

Intracranial Hemorrhage in Patients Receiving Factor Xa Inhibitors: Challenges and Perspectives. [PDF]

Intern Med
Chatani R.
europepmc   +1 more source

Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study. [PDF]

Front Neurol, 2023
Doeppner TR, Olbricht L, Maxhuni T, Alhaj Omar O, Sachs UJ, Juenemann MB, Huttner HB, Gerner ST.   +7 more
europepmc   +1 more source

Rational Design of Novel Isosteviol-Derived Factor Xa Inhibitors Using Integrated QSAR, Molecular Docking, Molecular Dynamics, and MM/GBSA Analyses. [PDF]

Biology (Basel)
Gordon P, Szeleszczuk Ł, Lasota M, Pisklak DM, Gackowski M.   +4 more
europepmc   +1 more source

Small-Molecule Factor Xa Inhibitors: Translational SAR, Assay-Aware Data Quality, and QSAR-Readiness for CADD-Oriented Discovery. [PDF]

Pharmaceuticals (Basel)
Gordon P, Janiak M, Mądra-Gackowska K, Wydeheft L, Hołyńska-Iwan I, Gackowski M.   +5 more
europepmc   +1 more source

Hospital Course and Outcomes After Major Bleeding in Patients on Factor Xa Inhibitors in Japan: A Nationwide Observational Study. [PDF]

J Atheroscler Thromb
Kohsaka S, Yasaka M, Hoshino M, Ide R, Wada F, Morita N.   +5 more
europepmc   +1 more source

Characteristics of Intracranial Hemorrhage in Patients on Factor-Xa Inhibitors: Japan Stroke Data Bank. [PDF]

Intern Med
Wada S, Yoshimura S, Torii-Yoshimura T, Miyazaki J, Arakaki Y, Yoshida Y, Inoue M, Katayama M, Morita K, Yagita Y, Miyamoto Y, Toyoda K, Koga M.   +12 more
europepmc   +1 more source

The 5 most frequently asked questions about factor Xa inhibitors. [PDF]

Hematology Am Soc Hematol Educ Program, 2022
Wang TF, Carrier M.
europepmc   +1 more source

Incomplete harms reporting in systematic reviews of direct oral factor Xa inhibitors. [PDF]

Blood Adv
Rea J, Lee C, Kee M, Rucker B, Flores H, Walters C, Haney T, Tomlin A, Khan A, Vassar M.   +9 more
europepmc   +1 more source